Linked Life Data

17511802

Source:http://linkedlifedata.com/resource/pubmed/id/17511802

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17511802rdf:typepubmed:Citationlld:pubmed
pubmed-article:17511802lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C0205216lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C0178587lld:lifeskim
pubmed-article:17511802lifeskim:mentionsumls-concept:C1442989lld:lifeskim
pubmed-article:17511802pubmed:issue1lld:pubmed
pubmed-article:17511802pubmed:dateCreated2008-1-14lld:pubmed
pubmed-article:17511802pubmed:abstractTextFor women diagnosed with ovarian cancer, the standard practice of surgery followed by adjuvant platinum-taxane combination chemotherapy, with cycles administered every 3 weeks, is based on randomized control trials. However, a substantial number of patients require delays or reductions on this schedule. The Cancer Centre of Southeastern Ontario (CCSEO) has historically administered chemotherapy every 4 weeks. We analyzed survival outcomes of our cohort. All ovarian cancer patients treated with chemotherapy at the CCSEO from 1995 to end-2002 were included in this study. Overall survival and progression-free survival were calculated from initiation of chemotherapy using the Kaplan-Meier technique and log-rank tests. Cox regression analysis was used to adjust for age and disease stage. A total of 171 patients were treated with chemotherapy (cisplatin-paclitaxel or carboplatin-paclitaxel), of which 144 received chemotherapy every 4 weeks and 27 every 3 weeks. Median progression-free survival was 19.2 months for the group treated every 4 weeks vs 13.2 months for the 3-weekly group. Median overall survival was 36.5 months compared to 27.1 months, respectively. Trends favored treatment every 4 weeks. In early-stage disease, 5-year overall survival was 74% and 5-year progression-free survival was 68%. Administration of platinum-paclitaxel chemotherapy every 4 weeks did not reduce survival of ovarian cancer patients. Importantly, median survival is favorable compared to results from landmark trials where patients were treated every 3 weeks. These results suggest that decreasing the frequency of chemotherapy cycles does not decrease survival. Prospective trials would be required to compare quality of life and cost-effectiveness.lld:pubmed
pubmed-article:17511802pubmed:languageenglld:pubmed
pubmed-article:17511802pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17511802pubmed:citationSubsetIMlld:pubmed
pubmed-article:17511802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17511802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17511802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17511802pubmed:statusMEDLINElld:pubmed
pubmed-article:17511802pubmed:issn1525-1438lld:pubmed
pubmed-article:17511802pubmed:authorpubmed-author:BrysonPPlld:pubmed
pubmed-article:17511802pubmed:authorpubmed-author:JeffreyJ FJFlld:pubmed
pubmed-article:17511802pubmed:authorpubmed-author:HopmanW MWMlld:pubmed
pubmed-article:17511802pubmed:authorpubmed-author:VijayS MSMlld:pubmed
pubmed-article:17511802pubmed:authorpubmed-author:MolckovskyAAlld:pubmed
pubmed-article:17511802pubmed:authorpubmed-author:BiagiJ JJJlld:pubmed
pubmed-article:17511802pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17511802pubmed:volume18lld:pubmed
pubmed-article:17511802pubmed:ownerNLMlld:pubmed
pubmed-article:17511802pubmed:authorsCompleteYlld:pubmed
pubmed-article:17511802pubmed:pagination8-13lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:meshHeadingpubmed-meshheading:17511802...lld:pubmed
pubmed-article:17511802pubmed:articleTitleDecreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.lld:pubmed
pubmed-article:17511802pubmed:affiliationDepartment of Oncology and Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada.lld:pubmed
pubmed-article:17511802pubmed:publicationTypeJournal Articlelld:pubmed